Aplastic Anemia, MDS, PNH Virtual Support Group-Saturdays-2026 March
AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with aplastic anemia aplastic anemia: (ay-PLASS-tik uh-NEE_mee-uh) A rare and serious co
Myeloproliferative Neoplasms (MPN)
Rusfertide Continues to Show Strong Results for Polycythemia Vera
Original Publication Date
Article Source
External Web Content
Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile. Treatment with the hepcidin mimetic rusfertide continued to demonstrate sustained hematocrit control below 45% and high…
Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML
Original Publication Date
Article Source
External Web Content
Key Takeaways The combination therapy achieved a 91% overall response rate, with 45% complete remission and 46% marrow complete remission rates. Median overall survival was 30 months, with 1- and 3-year survival rates of 68.8% and 40.7%, respectively. SHOW MORE Decitabine…
Understanding Bone Marrow & Stem Cell Transplants
This guide provides important information about bone marrow and stem cell transplantation
Understanding Clinical Trials
This guide provides information about clinical trials and gives you some things to consider when deciding whether to take part
Financial Resources
A list of organizations & programs that may provide financial resources & other assistance
ASH 2020
Bone Marrow Failure Disease Research Summaries for Patients from the 2020 American Hematology Society Annual Meeting
AAMDS Scientific Symposium 2020
Summary for patients from the seventh International Bone Marrow Failure Disease Scientific Symposium
Order Patient Educational Materials
AAMDSIF provides educational materials for patients and healthcare professionals written in plain language and reviewed by highly respected and recognized medical doctors who are experts in bone marrow failure
Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy
Original Publication Date
Article Source
External Web Content
Key Points Ivosidenib, venetoclax ± azacitidine either rapidly selects evolved, resistant leukemic clones or eradicates leukemic clones. Resistant clones express RNA signatures of stemness, branched-chain amino acid metabolism, and menin targets. Subjects:Myeloid Neoplasia…